Related Experiment Videos
Peptichemio induction therapy in myelomatosis
Cancer Chemotherapy and Pharmacology
|January 1, 1982
Summary
Peptichemio (PTC) combined with prednisone and androstanes showed significant effectiveness in treating multiple myeloma, including advanced and resistant cases. This combination therapy achieved a high response rate, suggesting its potential in initial and salvage treatments.
Area of Science:
- Hematology
- Medical Oncology
- Clinical Pharmacology
Background:
- Multiple myeloma is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
- Effective treatment strategies for advanced and alkylating agent-resistant multiple myeloma remain a clinical challenge.
Purpose of the Study:
- To evaluate the efficacy and tolerability of Peptichemio (PTC) in combination with prednisone and androstanes for multiple myeloma patients.
- To assess PTC's effectiveness in patients resistant to traditional alkylating agents like melphalan (MPH) and cyclophosphamide (CTX).
Main Methods:
- A cohort of 15 multiple myeloma patients received intravenous PTC (40-80 mg/48h) with prednisone (15-50 mg/day) and high-dose androstanes (250 mg weekly).
- Two patients received additional vincristine (VCR) on day one of PTC courses.
- Patient responses were evaluated based on predefined criteria.
Main Results:
- A total of 13 out of 15 PTC courses resulted in a response (8 complete, 5 partial).
- Three out of four MPH/CTX-resistant patients achieved responses, maintained with their previously resistant agents.
- The median time to achieve 90% of responses was 6 weeks.
Conclusions:
- Peptichemio demonstrates efficacy in advanced multiple myeloma, light-chain myeloma, and plasma cell leukemia.
- The combination of PTC with VCR enhanced antitumor effects but increased myelotoxicity.
- PTC is a well-tolerated option for induction therapy and for patients resistant to conventional alkylating agents.